DGIdb - HALOPERIDOL Drug Record

HALOPERIDOL chembl:CHEMBL54 Approved

Alternate Names:

DOLPIN
KENTACE
DOZIC
MCN-JR-1625
R-1625
NSC-170973
HALDOL SOLUTAB
NSC-615296
FORTUNAN
HALDOL
SERENACE
KESELEN
HALOPERIDOL
SERENACE®
GAMMA-(4-(P-CHLOROPHENYL)-4-HYDROXPIPERIDINO)-P-FLUORBUTYROPHENONE
4-[4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDYL]-1-(4-FLUOROPHENYL)-BUTAN-1-ONE
4'-FLUORO-4-(4-(P-CHLOROPHENYL)-4-HYDROXYPIPERIDINYL)BUTYROPHENONE
HALDOL®
HALOPERIDOLUM
Γ-(4-(P-CHLOROPHENYL)-4-HYDROXPIPERIDINO)-P-FLUORBUTYROPHENONE
4'-FLUORO-4-(4-HYDROXY-4-(4'-CHLOROPHENYL)PIPERIDINO)BUTYROPHENONE
4-(4-(PARA-CHLOROPHENYL)-4-HYDROXYPIPERIDINO)-4'-FLUOROBUTYROPHENONE
1-(3-P-FLUOROBENZOYLPROPYL)-4-P-CHLOROPHENYL-4-HYDROXYPIPERIDINE
chemidplus:52-86-8
pubchem.compound:3559
rxcui:5093
drugbank:00502
chembl:CHEMBL54

Drug Info:

Year of Approval	1967
Drug Class	antipsychotic agents
FDA Approval	1967
Drug Class	small molecule
Drug Indications	Antipsychotic Agents

(4 More Sources)

Publications:

Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Eastwood et al., 1996, The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain., Neurosci. Lett.
Ishiwata et al., 2006, A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors., Ann Nucl Med
Leysen et al., 1994, Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity., J Clin Psychiatry
Bustillo et al., 2006, Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels., Neuropsychopharmacology
Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
Osinski et al., 2005, Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets., Pharmacol. Biochem. Behav.
Seeman, 2010, Dopamine D2 receptors as treatment targets in schizophrenia., Clin Schizophr Relat Psychoses
Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Lipska et al., 2003, Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs., Eur. J. Neurosci.
Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
Jönsson EG et al., 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers., Mol Psychiatry
Pohjalainen T et al., 1998, The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers., Mol Psychiatry
Monteleone P et al., 2009, Management of schizophrenia with obesity, metabolic, and endocrinological disorders., Psychiatr Clin North Am
Hoenicka J et al., 2010, The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine., Biol Psychiatry
Blum K et al., 1990, Allelic association of human dopamine D2 receptor gene in alcoholism., JAMA
Kraschewski A et al., 2009, Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function., Pharmacogenet Genomics
Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
Doehring A et al., 2009, Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution., Pharmacogenet Genomics
Munafò MR et al., 2009, Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial., Nicotine Tob Res
Le Foll B et al., 2009, Genetics of dopamine receptors and drug addiction: a comprehensive review., Behav Pharmacol
Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
David SP et al., 2008, Genetic variation in the dopamine pathway and smoking cessation., Pharmacogenomics
Thelma B et al., 2008, Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics., Pharmacogenomics
Blum K et al., 1991, Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism., Alcohol
Huang W et al., 2009, Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample., Neuropsychopharmacology
Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
Smith L et al., 2008, Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review., Am J Epidemiol
Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
Swan GE et al., 2005, Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR., Pharmacogenomics J
Young et al., 2004, Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele., Br J Psychiatry
Xu K et al., 2004, Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations., Arch Gen Psychiatry
Neville MJ et al., 2004, Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1., Hum Mutat
Johnstone EC et al., 2004, Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch., Pharmacogenetics
Ritchie T et al., 2003, Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics., Neurochem Res
Schäfer M et al., 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene., Am J Psychiatry
Suzuki A et al., 2000, The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients., Pharmacogenetics
Mihara K et al., 2000, Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene., Psychopharmacology (Berl)
Kroeze et al., 2003, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs., Neuropsychopharmacology
Cai et al., 1999, Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein., Mol. Pharmacol.
Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
Sinor et al., 2000, NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro., J. Neurosci.
Hattori et al., 2006, Fyn is required for haloperidol-induced catalepsy in mice., J. Biol. Chem.
Steinmetz et al., 2002, A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands., J. Neurosci. Methods
Zhuravliova et al., 2007, Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity., Neurochem. Int.
Gallagher et al., 1998, Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions., J. Neurochem.
Gu et al., 2007, Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine., Acta Pharmacol. Sin.
Kessler et al., 2005, Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol., Neuropsychopharmacology
Malmberg et al., 1998, Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding., J. Pharmacol. Exp. Ther.
Tuppurainen et al., 2009, Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine., Psychiatry Clin. Neurosci.
Tadori et al., 2008, Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors., Eur. J. Pharmacol.
Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
Obuchowicz et al., 2005, Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity., Neuropeptides
de Bartolomeis et al., 2002, Acute administration of antipsychotics modulates Homer striatal gene expression differentially., Brain Res. Mol. Brain Res.
Fernø et al., 2006, Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs., BMC Neurosci
Gilbert et al., 2006, Nur77 gene knockout alters dopamine neuron biochemical activity and dopamine turnover., Biol. Psychiatry
O'Neill et al., 1998, Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine., J. Pharmacol. Exp. Ther.
Hanson et al., 1981, Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems., J. Pharmacol. Exp. Ther.
Noh et al., 2000, Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase., J. Neurochem.
Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
Zivković M et al., 2013, The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol., J Clin Psychopharmacol
Dean et al., 2006, Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia., Aust N Z J Psychiatry
Hajipour AR et al., 2011, Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand., Bioorg Med Chem
Cobos EJ et al., 2007, Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells., J Neurochem
Konkoy et al., 1996, Subchronic haloperidol administration decreases aminopeptidase N activity and [Met5]enkephalin metabolism in rat striatum and cortex., Eur. J. Pharmacol.
Zheng M et al., 2015, The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans., PLoS Med
Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
Katchman AN et al., 2006, Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs., J Pharmacol Exp Ther
Celano et al., 2003, Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs., Biol. Psychiatry
Fang et al., 1995, Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia., Psychopharmacology (Berl.)
Lara et al., 2001, Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats., Neuropsychobiology
Schmitt et al., 2003, Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain., Neurosci. Lett.
Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
Giegling I et al., 2011, Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol., Pharmacogenet Genomics
Chlan-Fourney et al., 2002, Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration., Brain Res.
Heiser et al., 2006, Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells., J Psychiatr Res

HALOPERIDOL SLC6A5

Interaction Score: 2.9

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 20859245

Sources:
PharmGKB
HALOPERIDOL ABCB5

Interaction Score: 2.9

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 25647612

Sources:
PharmGKB
HALOPERIDOL RGS2

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL RTKN2

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL TOR1A

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL PLEKHA6

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL ZIC4

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL AKAP13

Interaction Score: 1.93

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL HOMER1

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL NKX6-1

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL DPP6

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL ARID5B

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL DLG4

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11834303

Sources:
NCI
HALOPERIDOL HSPG2

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL IL1RN

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL EIF2AK4

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 24751813

Sources:
PharmGKB
HALOPERIDOL DTNBP1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL GRIK4

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL NPY

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16154634

Sources:
NCI
HALOPERIDOL SLC1A1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12873733

Sources:
NCI
HALOPERIDOL HTR3E

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL SIGMAR1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22055714 17419803

Sources:
DTC
HALOPERIDOL MC4R

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27217270 23920449 23799528 22566560

Sources:
PharmGKB
HALOPERIDOL DRD2

Interaction Score: 0.29

Interaction Types & Directionality:

inverse agonist (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Trial Name -

PMIDs:
17134027 7520908 16132064 16730699 15894081 20643630 17316700 11752352 12887421 21421319 27023437 10395223 9672901 19944883 19853839 1969501 19603545 19396436 19373123 19273465 19179847 18926547 18855532 18781857 18781856 1839129 18354387 18180754 18086475 17989061 17767146 15830237 15492764 15286066 15184239 15146457 15077009 12587665 11329406 10862524 10823405 12629531

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD
HALOPERIDOL EPM2A

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27092952

Sources:
PharmGKB
HALOPERIDOL NTS

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL GRIN2B

Interaction Score: 0.23

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
11102491 16407246 11741727 17092607 9572299 17588330 11752352 27023437

Sources:
PharmGKB
HALOPERIDOL NR4A1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16893530

Sources:
NCI
HALOPERIDOL ANPEP

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8851165

Sources:
NCI
HALOPERIDOL ANKK1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL RYR1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL GRIA1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8843098 27023437

Sources:
NCI PharmGKB
HALOPERIDOL NT5E

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11490180

Sources:
NCI
HALOPERIDOL CNR1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23799528 20631561 20107430

Sources:
PharmGKB
HALOPERIDOL CAMK2G

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12614997

Sources:
NCI
HALOPERIDOL FAAH

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20631561

Sources:
PharmGKB
HALOPERIDOL LDLR

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17052361

Sources:
NCI
HALOPERIDOL COMT

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 23963056

Sources:
PharmGKB
HALOPERIDOL DRD3

Interaction Score: 0.09

Interaction Types & Directionality:

inverse agonist (inhibitory)

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Direct Interaction yes

PMIDs:
16123775 7520908 9536001 19496999 18831971

Sources:
ChemblInteractions
HALOPERIDOL TAC1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6166743

Sources:
NCI
HALOPERIDOL GRIN2A

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL HSPA4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9864262

Sources:
NCI
HALOPERIDOL CACNA1C

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL HTR2C

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 12629531

Sources:
PharmGKB
HALOPERIDOL SLC6A4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 20031235

Sources:
PharmGKB
HALOPERIDOL GRIN1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL SLC2A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16002093

Sources:
NCI
HALOPERIDOL HTR3A

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL MAOB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7617809

Sources:
NCI
HALOPERIDOL SLC6A3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437

Sources:
PharmGKB
HALOPERIDOL DRD1

Interaction Score: 0.03

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
10531405 11752352 27023437

Sources:
DTC PharmGKB
HALOPERIDOL BDNF

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12393228

Sources:
NCI
HALOPERIDOL HTR2A

Interaction Score: 0.03

Interaction Types & Directionality:

other/unknown

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist

Direct Interaction yes

PMIDs:
7520908 12629531

Sources:
ChemblInteractions
HALOPERIDOL CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 18695978

Sources:
PharmGKB
HALOPERIDOL MAPK14

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11080184

Sources:
NCI
HALOPERIDOL DRD4

Interaction Score: 0.02

Interaction Types & Directionality:

inverse agonist (inhibitory)

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
HALOPERIDOL KCNH2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16278312

Sources:
DTC PharmGKB
HALOPERIDOL MTOR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HALOPERIDOL TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16476148

Sources:
NCI
HALOPERIDOL ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
HALOPERIDOL GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HALOPERIDOL CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HALOPERIDOL AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HALOPERIDOL CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: HALOPERIDOL
- Version: 01-August-2011
Alternate Names:

HALOPERIDOL Primary Drug Name

Drug Info:

Drug Class antipsychotic agents

Year of Approval 1967

Publications:
TdgClinicalTrial: HALOPERIDOL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antipsychotic Agents

Drug Class small molecule

FDA Approval 1967

Publications:

NCI: HALOPERIDOL

Version: 14-September-2017

Alternate Names:

C537 NCI drug code

Drug Info:

Publications:

O'Neill et al., 1998, Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine., J. Pharmacol. Exp. Ther.

Fang et al., 1995, Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia., Psychopharmacology (Berl.)

Schmitt et al., 2003, Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain., Neurosci. Lett.

DTC: HALOPERIDOL

Version: 02-September-2020

Alternate Names:

CHEMBL54 ChEMBL Drug ID

Drug Info:

Publications:

Hajipour AR et al., 2011, Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand., Bioorg Med Chem

Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

PharmGKB: haloperidol

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Zheng M et al., 2015, The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans., PLoS Med

TTD: Haloperidol
- Version: 2020.06.01
Alternate Names:

D0D1AL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL54
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL54
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	D2-like dopamine receptor inverse agonist
Trial Name	-

Mechanism of Interaction	Serotonin 2a (5-HT2a) receptor antagonist
Direct Interaction	yes

HALOPERIDOL Drug Record

HALOPERIDOL chembl:CHEMBL54 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437 20859245

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437 25647612

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11834303

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437 24751813

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27023437

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16154634

Interaction Types & Directionality:

n/a

PMIDs:
27023437 20859245

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437 25647612

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11834303

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437 24751813

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16154634

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12873733

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22055714 17419803

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
27217270 23920449 23799528 22566560

Sources:
PharmGKB

Interaction Types & Directionality:

inverse agonist (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction D2-like dopamine receptor inverse agonist

Trial Name -

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
27092952

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
11102491 16407246 11741727 17092607 9572299 17588330 11752352 27023437